Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed target EMERYVILLE, CA, UNITED STATES, January 6 ...
Ghent, Belgium – October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million ...
“Abalone Bio’s FAST platform’s capability to generate functionally active GPCR antibodies, presents an opportunity to push the boundaries of therapeutic antibody discovery,” said Richard Yu, PhD, ...
“Abalone Bio’s FAST platform’s capability to generate functionally active GPCR antibodies, presents an opportunity to push the boundaries of therapeutic antibody discovery,” said Richard Yu, PhD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results